Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3894 | TXA127 Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
There is surge in COVID infected patients in New York City with a shortage of hospital beds, ICU beds and ventilators. Strategies to reduce the need for all of the above are immediately needed. Further, few interventions are targeted in COVID infected patients early in the course of their disease and especially in the community/home settings. Respiratory decompensation appears to occur later in the disease process (i.e. 7-10 days after becoming symptomatic) therefore many patients are sent home from the Emergency Room and they subsequently decompensate later at home. Some patients die at home and others are returning to the Emergency Room with hypoxemic respiratory failure. There is no treatment offered to this population of patients, i.e. COVID suspected or confirmed and with respiratory symptoms or abnormal chest x-ray at the time of presentation. Based on experience across the globe, these patients are likely to worsen at home. The study team therefore proposes a prospective, single-center, parallel group, open-label, randomized clinical trial to assess the efficacy of fixed low continuous positive airway pressure therapy (CPAP) (FDA approved and often used for treatment of sleep apnea) in COVID confirmed or suspected patients with abnormal chest x-ray or respiratory symptoms who do not require hospital admission and are discharged home from the emergency room.
Description: Non-weighted composite score comprised of the following components: All-cause mortality within 14 days of randomization, hospital Admission (including ED visit) within 14 days of randomization, oxygen saturation less than 90 during the 72-hour observation period from randomization, absolute reduction in oxygen saturation of more than 4% during the 72-hour observation period from randomization.
Measure: Efficacy Endpoint composite score Time: 14 daysDescription: The time from randomization to an admission to the intensive care unit within 14 days from randomization
Measure: Time to ICU admission Time: 14 days from randomizationDescription: The time from randomization to the patient needing to be intubated and needing mechanical ventilation within 14 days from randomization
Measure: Time to Intubation and mechanical ventilation Time: 14 days from randomizationDescription: The time from randomization to death within 14 and 28 days from randomization
Measure: 14 day and 28 day mortality Time: 14-28 days from randomizationDescription: The conversation rate of household members from being COVID negative to COVID positive in the CPAP arm vs the control arm within 14 days from randomization
Measure: Conversion rate of COVID household members in CPAP vs control Time: 14 days from randomizationDescription: If there is any improvement in respiratory symptoms of cough or shortness of breath etc. assessed via a respiratory symptom questionnaire within 14 days from randomization. The CCQ is a 10-item instrument, full scale from 0 to 6, with higher score indicating lower health status.
Measure: Clinical COPD Questionnaire (CCQ) Time: 14 days from randomizationDescription: Percentage of the patients in the CPAP arm elect to continue using the CPAP after the initial 72 hour period.
Measure: Percentage of patients electing to continue CPAP for greater than 72 hours Time: 7 days from randomizationDescription: The degree of improvement in oxygen saturation within 14 days of randomization.
Measure: Degree of improvement in oxygen saturation Time: 14 days from randomizationDescription: Time to hospital admission or ED within 14 days of randomization
Measure: Time to hospital admission or ED Time: 14 days from randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports